More than 70% of patients with temporal lobe epilepsy (TLE) recall their dreams, but their dream recall rate is lower than that of healthy controls. Dream recall is not influenced by neuropsychological deficits or seizure frequency. Compared to controls, TLE patients report dreams with a higher percentage of familiar settings and fewer dreams involving success. These findings suggest that mesial and neocortical temporal structures play a role in dream experience, and that selective activation of dysfunctional mesial structures may contribute to variability in dream recall. Dream content changes may also reflect social and psychological comorbidities of epilepsy.
Psilocybin, a hallucinogen known for its therapeutic potential in psychiatry, has shown remarkable promise in reducing depression. In a sample of 200 participants, 70% reported significant improvements in mood after treatment. Additionally, psilocybin was associated with a 50% decrease in suicidal thoughts among those with severe depression. This medicine not only offers hope for pain management but also raises intriguing questions about the placebo effect and its implications for mental health economics. Enhanced understanding could reshape approaches to suicide prevention and psychological well-being.